Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

06 May 2020

Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.

The analysis included 478 patients, of whom 240 were treated with carfilzomib once-weekly at 70 mg/m2 and 238 with twice-weekly at 27 mg/m2 in addition to dexamethasone. Baseline characteristics were generally balanced between treatment arms across subgroups. Researchers performed subgroup analyses defined by age (<65, 65–74, or ≥75 years), renal function (creatinine clearance <50, ≥50–<80, or ≥80 mL/min), number of prior therapies (two or three) and bortezomib-refractory status (yes or no).

Overall, the once-weekly regimen increased progression-free survival (median, 11.2 vs 7.6 months; hazard ratio [HR], 0.69, 95 percent confidence interval [CI], 0.54–0.88; p=0.0029) compared with the twice-weekly regimen, as it did response rates and depth of response.

Furthermore, the once-weekly regimen reduced the risk of progression or death (HR range, 0.60–0.85) and improved overall response rates in nearly all the examined subgroups. This was consistent with the results in the overall population.

The safety profiles of once-weekly dosing across subgroups were also in line with those observed in the overall population.

The present data highlight a favourable benefit–risk profile of once-weekly 70-mg/m2 carfilzomib regimen and support such dosing as an appropriate treatment option for patients with RRMM, regardless of age, prior lines of therapy and bortezomib-refractory status, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.